Therapeutic potentials of angiostatin in the treatment of cancer

Haematologica

Volumn 84, Issue 7, 1999, Pages 643-650

  Cao, Yihai ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angiostatin; Neoplasms; Treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ENDOSTATIN; FIBRONECTIN; PLASMINOGEN; PROLACTIN; THROMBOCYTE FACTOR 4;

ANTINEOPLASTIC ACTIVITY; CANCER; GENE THERAPY; HUMAN; KRINGLE DOMAIN; NONHUMAN; PROTEIN DEGRADATION; REVIEW; TUMOR VASCULARIZATION;

ANGIOSTATINS; ANIMALS; GENE THERAPY; HUMANS; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN;

EID: 0032798298     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64.
2. Folkman J. Angiogenesis in Cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1:27-31.
3. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-63.
4. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Comm 1992; 189:824-31.
5. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25.
6. Nguyen M, Watanabe H, Budson AE, Richle JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86:356-61.
7. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265:1582-4.
8. Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997; 89:219-27.
9. O'Reilly MS, Holmgren L, Shine Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-28.
10. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:1-20.
11. Cao Y, Chen C, Weatherbee JA, Tsang M, Folkman J. gro-beta, a -C-X-C-chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. J Exp Med 1995; 182:2069-77.
12. Ribatti D, Vacca A, Iurlaro M, Ria R, Roncali L, Dammacco F. Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture. Int J Microcir Clin Exp 1996; 16:165-9.
13. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87:581-6.
14. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182:155-62.
15. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock 1995; 4:155-60.
16. Maione TE, Gray GS, Petro AJ, Hunt AL, Donner SI. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247:77-9.
17. Jackson D, Volpert OV, Bouck N, Linzer DIH. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin related protein. Science 1994; 266:1581-4.
18. Hanneken A, Ying W, Ling N, Baird A. Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Natl Acad Sci USA 1994; 91:9170-4.
19. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87:6624-8.
20. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990; 248:1408-10.
21. Clapp C, Martial JA, Guzman RC, Rentierdelrue F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endorinology 1993; 133:1292-9.
22. Cao Y, Chen A, An SSA, et al. Kringle 5 of plasminogen: a novel inhibitor of endothelial cell growth. J Biol Chem 1997; 272:22924-8.
23. Brooks PC, Silletti S, Schalscha TL, Friedlander M, Cheresh D. Disruption of angiogenesis by PEX, a non-catalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92:391-400.
24. Cao R, Wu H-L, Veitonmäki N, et al. Supression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999; 96:5728-33.
25. Moses MA, Wiederschain D, Wu I, et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci USA 1999; 96:2545-50.
26. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2:689-92.
27. Cao Y, Ji R-W, Davidson D, et al. Kringle domains of human plasminogen: Characterization of the anti-proliferative activity of endothelial cells. J Biol Chem 1996; 271:29461-7.
28. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997; 88:801-10.
29. Gately S, Twardowski P, Stack MS, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1997; 56:4887-90.
30. Sim BKL, Oreilly MS, Liang H, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997; 57:1329-34.
31. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-53.
32. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji WR, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998; 101:1055-63.
33. Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Career Res 1998; 58: 3362-9.
34. Liu Y, Thor A, Shtivelman E, et al. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J Biol Chem 1999; 274:13338-42.
35. D'Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 1995; 92:6374-8.
36. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci 1995; 92:7799-803.
37. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
38. Holmandberg GA, Williams JE, Grant DBS, Eisenstein R. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. J Am Path 1985; 120:327-32.
39. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367:576-9.
40. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-64.
41. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct av integrins. Science 1995; 270:1500-2.
42. Maione TE, Gray GS, Hunt AJ, Donner AL, Sharpe RJ. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 1991; 51:2077-83.
43. Luster AD, Leder P. IP-10, a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993; 178:1057-65.
44. Ezekowitz RAB, Mulliken J, Folkman J. Interferon-α2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1994; 330:300.
45. Ezekowitz RAB, Mulliken J, Folkman J. Interferon-α2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1995; 333:595-6.